22 citations
,
November 2005 in “BMC Cancer” Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.
2 citations
,
December 2015 in “DOAJ (DOAJ: Directory of Open Access Journals)” Targeted anticancer therapies often cause skin issues, affecting treatment adherence and quality of life.
13 citations
,
September 2022 in “Frontiers in immunology” Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
36 citations
,
October 2019 in “Cell Proliferation” Tryptanthrin effectively suppresses non-melanoma skin cancer and is safe for normal skin.
January 2024 in “Wiadomości Lekarskie” Low-penetration genes might help personalize colorectal cancer prevention.
May 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” Nicastrin deficiency may cause skin cell damage and pigmentation disorders in humans, similar to effects seen in fish.
January 2024 in “International Journal of Dermatology Venereology and Leprosy Sciences” Tofacitinib may be safe and effective for treating certain skin conditions in children.
March 2022 in “International Journal of Trichology” Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
11 citations
,
February 2022 in “JAAD case reports” Abrocitinib, a JAK inhibitor, may help treat atopic dermatitis and alopecia universalis together.
10 citations
,
January 2023 in “SAGE Open Medical Case Reports” Upadacitinib may effectively treat both alopecia universalis and Crohn's disease.
1 citations
,
March 2011 in “Journal of Investigative Dermatology” Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.
July 2025 in “Journal of the European Academy of Dermatology and Venereology” 1 citations
,
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is effective and safe for long-term treatment of alopecia areata.
August 2020 in “Ugeskrift for Læger” A man with severe hair loss regrew all his hair using tofacitinib and stayed healthy for a year.
2 citations
,
July 2023 in “JAAD Case Reports” A woman with a type of hair loss saw hair regrowth after two months of taking baricitinib.
September 2023 in “Journal of The American Academy of Dermatology” Baricitinib shows promise in treating severe hair loss.
79 citations
,
October 2003 in “PubMed” Overexpression of PKCepsilon leads to increased TNFalpha, promoting metastatic squamous cell carcinoma in mice.
January 2024 in “Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica/Revista de la Asociacion Colombiana de Dermatologia y Cirugia Dermatologica” Baricitinib successfully treated severe hair loss.
January 2022 in “Dermatology Review” EGFR inhibitors can cause unusual localized hair growth.
1 citations
,
January 2023 in “Bioscience Journal” Sorafenib and Platycladus orientalis leaf extract together effectively suppress cervical cancer cell growth.
October 2025 in “Zenodo (CERN European Organization for Nuclear Research)” Ritlecitinib may help young adults with severe alopecia areata when ketoconazole fails.
May 2025 in “Dermatology Online Journal” Erlotinib can cause excessive eyelash growth.
1 citations
,
January 2025 in “CPT Pharmacometrics & Systems Pharmacology” Ritlecitinib effectively regrows eyebrow and eyelash hair in alopecia areata, with 50 mg being the best dose.
6 citations
,
September 2024 in “Current Oncology” Sacituzumab Govitecan is effective for certain breast cancers but requires careful management of side effects.
18 citations
,
July 2023 in “International Journal of Molecular Sciences” KY19382 speeds up wound healing by activating a specific cell signaling pathway.
1 citations
,
April 2018 in “The journal of investigative dermatology/Journal of investigative dermatology” Topical patidegib gel effectively treats basal cell carcinoma in Gorlin syndrome patients without causing the side effects seen with oral treatments.
12 citations
,
January 2016 in “Journal of clinical biochemistry and nutrition” Deferasirox combined with sorafenib reduces liver cancer risk and lessens treatment side effects.
4 citations
,
August 2023 in “Biomedicine & Pharmacotherapy” Ivacaftor can protect against noise-induced hearing loss by reducing oxidative stress.
45 citations
,
January 2012 in “The Journal of Steroid Biochemistry and Molecular Biology” Too much AKR1C3 enzyme causes resistance to finasteride by increasing testosterone.
December 2024 in “Naunyn-Schmiedeberg s Archives of Pharmacology”